Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Azelastine Hydrochloride

FDA-approved product (spray, metered, nasal), marketed as Astelin, Astepro, Astepro Allergy and 5 more.

Registered studies
48
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Azelastine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic disease
  • Allergic rhinitis
  • Eye allergy
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Vasomotor rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiallergic agents, excl. corticosteroids; Other antihistamines for systemic use; Other antiallergics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

48registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Azelastine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Azelastine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

    NCT00712920 · start 2007-01

    Registered record
    Registry ID
    NCT00712920
    Conditions
    Perennial Allergic Rhinitis
    Interventions
    0.15% azelastine hydrochloride; 0.1% azelastine hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-01
    Completion
    Not recorded
    Enrolment
    581

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis
    Intervention0.15% azelastine hydrochloride; 0.1% azelastine hydrochloride; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

    NCT01368445 · start 2006-08

    Registered record
    Registry ID
    NCT01368445
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    azelastine hydrochloride 0.15% Nasal Spray; azelastine hydrochloride 0.15% and Placebo; Azelastine 0.1%, Nasal Spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-08
    Completion
    2008-04
    Enrolment
    617

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    Interventionazelastine hydrochloride 0.15% Nasal Spray; azelastine hydrochloride 0.15% and Placebo; Azelastine 0.1%, Nasal Spray
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

    NCT00783432 · start 2006-07

    Registered record
    Registry ID
    NCT00783432
    Conditions
    Chronic Allergic Rhinitis; Nonallergic Rhinitis
    Interventions
    Astepro Nasal Spray (0.1% azelastine hydrochloride); Astelin Nasal Spray (0.1% azelastine hydrochloride)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2007-12
    Enrolment
    862

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Allergic Rhinitis; Nonallergic Rhinitis
    InterventionAstepro Nasal Spray (0.1% azelastine hydrochloride); Astelin Nasal Spray (0.1% azelastine hydrochloride)
    PhasePhase 3
    Registry statusCompleted